Clinical Trial Update: ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating veliparib (ABT-888) in combination with temozolomide for pediatric patients with recurrent or refractory CNS tumors; the trial has co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Childhood Atypical Teratoid Rhabdoid Tumor
• Childhood Central Nervous System Germ Cell Tumor
• Childhood Choroid Plexus Tumor
• Childhood Craniopharyngioma
• Childhood Ependymoma
• Childhood Medulloblastoma
• Childhood Meningioma
• Childhood Oligodendroglioma

Drugs mentioned

• Temodar (Temozolomide)
• Veliparib (veliparib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Germ Cell Tumor | Phase 1 | Status: COMPLETED